
© Magnific
November 15, 2026
Marianne Waldenfels
NAD+ is a major focus of the longevity industry, with celebrities and biohackers investing in costly supplements and infusions. But what can these treatments actually achieve? Several studies published in 2026 offer new insights – including a finding that surprised even the researchers themselves.
It is one of the great promises of the longevity scene: a single molecule, it is claimed, can revitalize tired cells and slow biological aging. The substance is called NAD+, and it is sold as a capsule, powder, or infusion. Biohackers like Bryan Johnson are intensely focused on it, and at longevity clinics, customers sometimes pay considerable sums for the corresponding infusions.
The rationale sounds plausible: NAD+ levels decline with age — there is even frequent talk of levels halving by middle age. The logical response, then, is simply to top them up. In 2026, however, several research groups decided to take a closer look.
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell of the body. Without it, the mitochondria, the cell's powerhouses, cannot generate energy. It also plays a central role in repairing DNA damage.
The hype began roughly 20 years ago, sparked by experiments in yeast, worms, and mice: interventions in NAD+ metabolism produced promising effects on aging processes — and in some cases on lifespan — across a range of model organisms. Most supplements on the market today use precursors from which the body synthesizes NAD+ itself, primarily nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). Both are derivatives of vitamin B3.
That these precursors have an effect — at least on NAD+ metabolism in the blood — is now well established. A study led by Nestlé researchers involving 65 healthy adults, published in early 2026 in the journal Nature Metabolism, showed that NR and NMN raise blood NAD+ levels comparably within just 14 days. The key question, however, is a different one: does the body actually benefit?
Ironically, it was researchers who originally set out to develop an NAD+ test who have now undermined the trend's central premise. The team led by Maria Trętowicz and Riekelt Houtkooper at Amsterdam UMC wanted to explore whether blood NAD+ levels could serve as a marker of biological age. To do so, they analyzed blood samples from seven independent datasets comprising more than 300 people in total, ranging from frail elderly individuals to elite athletes.
Their findings, published in June 2026 in Nature Metabolism, revealed no general decline in whole-blood NAD+ levels with increasing age across the datasets examined. No meaningful differences were found between elite athletes and less active individuals either. The study provides "important clarity in a field full of contradictory reports, hype, and commercial promises," the authors write.
There is, however, one important caveat: blood does not necessarily reflect what is happening in the organs. Earlier studies — including one from Houtkooper's own group — did find lower NAD+ levels in the muscles of older individuals. How much levels decline in which tissues, and what health consequences this carries, remains an open question.
The oft-repeated claim that NAD+ levels generally halve with advancing age cannot therefore be applied to the body as a whole.
Even more striking are the findings of clinical studies published in 2026. Three investigations involving very different groups of participants tell a similar story: the supplements do influence NAD+ metabolism, yet no convincing health benefit was demonstrated for the endpoints examined.
The largest study to date on an NAD+ booster in a neurological condition was conducted in Norway. In the NOPARK trial, 410 people with early-stage Parkinson's disease at eleven clinics received either 500 milligrams of NR twice daily or a placebo for one year. Animal studies and smaller trials had suggested that modulating NAD+ metabolism might protect the affected nerve cells.
The results, published in October 2026 in the journal JAMA, were sobering. After 52 weeks, Parkinson's symptoms had worsened statistically significantly more in the NR group than in the placebo group — though the difference of 2.72 points fell below the threshold considered clinically meaningful. Non-motor symptoms also fared worse in the NR group. Serious adverse events, on the other hand, did not occur more frequently with NR than with placebo. No therapeutic benefit could be demonstrated.
One further detail is telling: while NR did raise blood NAD+ levels, levels in the brain showed no measurable change after one year. Although NR significantly affected NAD+ metabolism, this did not translate into any clinical improvement. The research team led by Charalampos Tzoulis of the University of Bergen therefore advises Parkinson's patients against taking NR or other NAD+ boosters outside of controlled trials.
In Japan, researchers at the University of Tokyo tested high-dose NMN in 62 healthy individuals over the age of 65. Participants took 1,250 milligrams of NMN or a placebo daily for 24 weeks. A wide range of potential markers of healthy aging were examined: hearing ability, endurance in the six-minute walk test, epigenetic age, gut microbiota, and quality of life.
According to the study, published in September 2026 in npj Aging, NAD+ levels rose significantly throughout the entire period. However, no significant benefit was observed for either hearing function or physical performance. Individual changes in body composition and blood lipid levels lost their statistical significance after correction for multiple comparisons.
This is also noteworthy because an NMN manufacturer funded the study and supplied the supplement. That said, the study was relatively small, with only 62 participants, so rare or minor effects cannot be ruled out entirely.
A similar picture emerged from a study by the University of Delaware, published in July 2026 in the journal Alzheimer's & Dementia. Older adults with mild cognitive impairment, which can be a precursor to dementia, took NR for twelve weeks.
Their NAD+ levels rose. However, memory performance, cardiovascular function, and overall cerebral blood flow did not improve significantly. Only in hippocampal blood flow — a brain region important for memory — was there a hint of a possible effect.
These results do not mean that NAD+ precursors are fundamentally ineffective. They do show, however, that the widely promoted improvements in health and performance cannot yet be convincingly derived from higher blood levels.
Anyone purchasing NAD+ supplements in Germany should also be aware of the relevant legal distinctions. Not all of the substances on offer may legally be sold as dietary supplements in Germany.
• NR: Nicotinamide riboside chloride is approved in the EU as a novel food for certain uses, including dietary supplements. Specific conditions and maximum quantities apply.
• NMN: Nicotinamide mononucleotide has not yet been approved as a novel food and, according to the Consumer Advice Centre, may not be placed on the market as a dietary supplement. In May 2026, the European Food Safety Authority (EFSA) issued a positive safety assessment for a specific NMN product; however, the corresponding EU authorization is still pending. NMN is nonetheless widely available online.
• NADH: The reduced form of NAD is also used in dietary supplements. However, there are no approved specific health claims for NADH or NAD+ that promise rejuvenation or improved performance.
One fundamental distinction is worth noting: a novel food authorization assesses the safety of a substance under specific conditions of use — not its efficacy as an anti-aging agent. This point is also made by the Consumer Advice Centre.
The evidence is even thinner when it comes to infusions that deliver NAD+ directly into the bloodstream. Meaningful clinical studies demonstrating an anti-aging or wellness effect are still lacking.
The findings from studies on NR and NMN cannot be straightforwardly applied to infusions, since the active compounds enter the body by different routes and may be metabolized differently. Whether the complex and costly intravenous route offers any benefit to healthy individuals therefore remains an open question.
For medical research, NAD+ metabolism remains a promising avenue. The NOPARK authors emphasize that their results do not rule out a benefit in other diseases.
NAD+ boosters are being investigated, for example, in rare metabolic and mitochondrial disorders in which NAD+ homeostasis is demonstrably disrupted. In the case of Long COVID, a small study from Mass General Brigham also produced tentative early indications of reduced fatigue and brain fog. However, only 18 of the 58 participants completed the study, so robust conclusions cannot yet be drawn.
For healthy individuals seeking to extend their healthspan, however, the picture looks meager. Even Riekelt Houtkooper, who continues to research NAD+, reportedly sees no reason — according to a report in the New York Times — to take such supplements.
NAD+ research is thus confronted with an uncomfortable conclusion: a molecule can be indispensable for life without an extra dose of it extending that life. So far, the studies show above all how reliably certain blood values can be altered. Whether this translates into people aging more healthily is an entirely different question.

Artificial intelligence, digital diagnostics, and new technologies are transforming medicine. At the Digital Health Summit 2026 in Munich, leading scientists, physicians, founders, and investors explored how to turn cutting-edge research into better patient care — and why collaboration among Munich's leading institutions is key to making it happen
PMC Redaktion

With
Univ.-Prof. Dr. med. Dominik Pförringer

An injection for osteoarthritis pain – but which treatments actually make a difference? Orthopedic specialist Dr. Ferzan Süzer explains why she rarely uses cortisone for degenerative joint disease, what research reveals about hyaluronic acid and platelet-rich plasma, and why injections alone are not enough.
Christine Bürg & Marianne Waldenfels

An interview with
Dr. med. Ferzan Süzer

"Feel Good, Live Better" – In this episode, Dr. Birgit Dinnewitzer explains why small intestinal bacterial overgrowth is so often mistaken for irritable bowel syndrome.
Christine Bürg

An interview with
Dr. Birgit Dinnewitzer